In the context of pancreatogenic diabetes, reduced chemerin levels correlate with increased insulin resistance, while treatment with the CMKLR1 agonist chemerin-9 improves glucose tolerance and restores GLUT2 and PDX1 expression, suggesting a protective role for chemerin signaling [89]. Here, RARRES2 is linked to Insulin resistance.